Scribe Therapeutics Q3 Net Loss Widens 52% to $9.9 Million
Scribe Therapeutics reported a Q3 2026 net loss of $9.9 million, 52% wider quarter over quarter.
Scribe Therapeutics reported a Q3 2026 net loss of $9.9 million, 52% wider quarter over quarter.